Table 2.
Association of family history manifestations with HLA-B27 in CBP patients in the SPACE (n = 438) and DESIR cohorts (n = 647)
| SPACE* | DESIR** | |||||||
|---|---|---|---|---|---|---|---|---|
| HLA-B27 + n = 174 | HLA-B27– n = 262 | OR (95% CI) | P value | HLA-B27 + n = 376 | HLA-B27– n = 270 | OR (95% CI) | P value | |
| Any PFH | 97 | 87 | 2.5 (1.7–3.8) | <0.001 | 158 | 91 | 1.4 (1.0–2.0) | 0.032 |
| AS | 65 | 24 | 5.9 (3.5–9.9) | <0.001 | 100 | 27 | 3.3 (2.1–5.2) | <0.001 |
| AAU | 23 | 4 | 9.8 (3.3–28.9) | <0.001 | 28 | 1 | 21.6 (2.9–160.1) | 0.003 |
| ReA | 5 | 9 | 0.8 (0.3–2.5) | 0.745 | 1 | 5 | 0.1 (0.01–1.2) | 0.075 |
| IBD | 12 | 21 | 0.9 (0.4–1.8) | 0.666 | 17 | 15 | 0.8 (0.4–1.6) | 0.551 |
| Psoriasis | 34 | 48 | 1.1 (0.6–1.8) | 0.750 | 69 | 60 | 0.8 (0.5–1.2) | 0.225 |
*Two patients with unknown HLA-B27 status
**One with patient unknown HLA-B27 status
AAU acute anterior uveitis, AS ankylosing spondylitis, CBP chronic back pain, CI confidence interval, HLA-B27 human leukocyte antigen B27, IBD inflammatory bowel disease, OR odds ratio, PFH positive family history (manifestation in first- or second-degree relatives), ReA reactive arthritis